Analysed ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) News Sources
Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial
11-06-2026
yahoo.com
Enliven Therapeutics Reports Positive Phase 1 CML Data and FDA Alignment for Phase 3 Trial (ELVN)
11-06-2026
advfn.com
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
11-06-2026
yahoo.com
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
12-06-2026
yahoo.com
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development
12-06-2026
stocktwits.com
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
15-06-2026
yahoo.com
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
27-06-2026
fool.com
What is the current price of ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ)?
The current price of ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) is $60.5.
ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) absolute price change since previous trading day?
The absolute price change of ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) since the previous trading day is $-0.365.
ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) percentage price change since previous trading day?
The percentage price change of ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) since the previous trading day is -0.5997%.
What is the most recent average sentiment score for ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ)?
The most recent average sentiment score for ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ)?
The most recent sentiment for ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ) is .
SEC-8K** Filing Available For ENLIVEN THERAPEUTICS INC (ELVN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.